Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer By Ogkologos - April 21, 2026 117 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Strategy May Prevent Tumor Resistance to Targeted Cancer Therapies March 17, 2023 Radiation-Induced ‘Genomic Scars’ Associate with Poor Patient Outcome October 9, 2020 10 Ways to Brave Cancer Treatment: Tips from a Survivor September 27, 2022 Aggressive Prostate Cancer Subtype More Common Than Expected July 31, 2018 Load more HOT NEWS Transforming Cancer Clinical Trials for Better, Faster Results EMA Recommends Granting a Conditional Marketing Authorisation for Belantamab Mafodotin ¿Puede protegerlo un “bronceado base” de las quemaduras solares y del... Off Target: Investigating the Abscopal Effect as a Treatment for Cancer
